Trends in risks associated with new drug development: success rates for investigational drugs

Clinical Pharmacology and Therapeutics
J A DiMasiA Wilson

Abstract

This study utilizes both public and private data sources to estimate clinical phase transition and clinical approval probabilities for drugs in the development pipelines of the 50 largest pharmaceutical firms (by sales). The study examined the development histories of these investigational compounds from the time point at which they first entered clinical testing (1993-2004) through June 2009. The clinical approval success rate in the United States was 16% for self-originated drugs (originating from the pharmaceutical company itself) during both the 1993-1998 and the 1999-2004 subperiods. For all compounds (including licensed-in and licensed-out drugs in addition to self-originated drugs), the clinical approval success rate for the entire study period was 19%. The estimated clinical approval success rates and phase transition probabilities differed significantly by therapeutic class. The estimated clinical approval success rate for self-originated compounds over the entire study period was 32% for large molecules and 13% for small molecules. The estimated transition probabilities were also higher for all clinical phases with respect to large molecules.

References

May 1, 1992·Bio/technology·B Bienz-TadmorL Lasagna
Nov 1, 1984·Clinical Pharmacology and Therapeutics·L SheckR Hansen
Jul 1, 1995·Clinical Pharmacology and Therapeutics·J A DiMasi
Jun 8, 1991·Journal of Health Economics·J A DiMasiL Lasagna
May 24, 2001·Clinical Pharmacology and Therapeutics·J A Dimasi
May 24, 2001·Clinical Pharmacology and Therapeutics·J A Dimasi
Feb 28, 2003·Journal of Health Economics·Joseph A DiMasiHenry G Grabowski
Aug 3, 2004·Nature Reviews. Drug Discovery·Ismail Kola, John Landis
Sep 23, 2008·American Journal of Therapeutics·Kenneth A GetzKenneth I Kaitin
Dec 17, 2008·Current Pharmaceutical Biotechnology·Janice M Reichert

❮ Previous
Next ❯

Citations

Aug 25, 2012·Digestive Diseases and Sciences·Alan R ZinsmeisterMichael Camilleri
Feb 9, 2013·Nature Biotechnology·Christopher Scott
Nov 12, 2013·Nature Biotechnology·Laura McNamee, Fred Ledley
Jan 10, 2012·Nature Medicine·Richard S BlumbergFrank O Nestle
Oct 12, 2012·Science Translational Medicine·Steven E Hyman
Mar 29, 2013·Science Translational Medicine·Jennifer A Gorzelany, Mark P de Souza
Dec 10, 2013·Hematology·Burt Adelman
Sep 12, 2012·Theoretical Biology & Medical Modelling·Ray Greek, Mark J Rice
Apr 10, 2012·The AAPS Journal·Thomayant Prueksaritanont, Cuyue Tang
Mar 26, 2013·PloS One·Esther S PronkerAlbertus D M E Osterhaus
Sep 26, 2013·International Journal of Environmental Research and Public Health·Michelle Marie LockhartSanjay Garg
May 23, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Demissie AlemayehuCharles A Knirsch
Jan 11, 2014·Nature Biotechnology·Michael HayJesse Rosenthal
Jul 24, 2012·Regenerative Medicine·Emily J Culme-SeymourChris Mason
Mar 13, 2013·Nanomedicine·Catherine A SchützUNKNOWN NanoImpactNet Consortium
May 31, 2014·Science·Thomas J HwangAaron S Kesselheim
Jun 19, 2014·Proceedings of the National Academy of Sciences of the United States of America·Valen E Johnson
Aug 19, 2014·Rejuvenation Research·João Pedro de Magalhães
Feb 14, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Eric S MartinKenneth E Hung
Sep 1, 2010·Expert Review of Clinical Pharmacology·Ingolf Cascorbi
Sep 12, 2015·Expert Opinion on Drug Discovery·Tao WangLi-Rong Yang
Nov 23, 2012·Expert Opinion on Drug Safety·Hugo M VargasMichael J Engwall
Jan 26, 2016·Pharmacogenomics·Lydia Wt Cheung, Gordon B Mills
Jan 16, 2016·Cardiovascular Drugs and Therapy·Marie-Pierre DubéJean-Claude Tardif
Nov 21, 2015·Chemical Research in Toxicology·Eric Blomme, Yvonne Will
Dec 23, 2014·MAbs·Dawn M EckerHoward L Levine
Jul 8, 2015·Advanced Drug Delivery Reviews·Kathleen RodgersNicholas Mordwinkin
Oct 13, 2012·Journal of Clinical Pharmacy and Therapeutics·K HayashiH Kimura
Oct 10, 2013·Pharmaceutical Statistics·Jianliang Zhang, Jenny J Zhang
Aug 6, 2010·The Mount Sinai Journal of Medicine, New York·Garret A FitzGerald
May 13, 2014·Clinical and Translational Science·Marci D CottinghamJill A Fisher
Jul 22, 2014·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Matthew Herder
Oct 30, 2013·Journal of Clinical Pharmacology·Mari ShirotaniKoji Chiba
Aug 1, 2015·CPT: Pharmacometrics & Systems Pharmacology·D R MouldB Frame

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.